Our History & Vision

Founded in 1992, Silver Lake Research has a proud history of continuous innovation, introducing transformative diagnostic solutions for human and animal health, environmental monitoring, and food safety. Today, our US-based development and manufacturing facilities produce millions of tests per year, with a robust pipeline promising an exciting future. Through strategic partnerships and collaborations, our strategic investments and groundbreaking research will pave the way for transformational solutions in diagnostics and beyond.

Our Technology

Enhanced Affinity Platform™ (EAP 4-Step System)

Step 1: Initial Antigen
Modification

Step 2: Host Pre-Treatment

Step 3: Immunization Application

Step 4: Massive Antibody Response

The antigen of interest is first modified with a proprietary SLR protocol, yielding a formulation that is hundreds-to-thousands of times more immunogenic than in standard immunization protocols.

Hosts are treated with congruent immune system modifiers, priming for recognition and response to the modified antigen.

The modified antigen is introduced to pre-treated hosts, using a proprietary SLR protocol.

The EAP System generates antibody responses that are orders of magnitude more potent than standard yields. The resulting monoclonal antibodies are of the highest quality, sensitivity, and specificity.

At Silver Lake Research, we use our powerful Enhanced Affinity Platform to create diverse monoclonal antibody (MAb) panels for detection of traditionally “difficult” or non-immunogenic targets. The EAP™ System was designed to generate a massive immune response to any target antigen – orders of magnitude more potent than standard immunization schemes.

SLR’s engineering expertise and vertical integration allow for the cost-effective development and manufacturing of simple, rapid, and highly sensitive lateral flow assay (LFA) test strips. These LFAs bring the power of laboratory testing into the palm of your hand, for confident antigen detection, in the home or out in the field. Importantly, the resulting rapid test kit products are affordable even in resource-constrained regions of the world.

Since 1992, SLR has been a global industry leader in MAb- and LFA-development. Our rapid test products are sold on six continents and are being deployed by governmental organizations and NGOs for public health screening and veterinary disease surveillance. Our outstanding track record of success in contract development projects makes us a trusted resource for the government and private industry partners. We look forward to collaborating with your group to develop the next important rapid test.